Taking people in NetherlandsPhase 1
Tests a radioactive medicine, 225Ac-PSMA I&T, in men with spreading prostate cancer
Tests a radioactive medicine, 225Ac-PSMA I&T, in adults with spreading prostate cancer.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- Rotterdam, NetherlandsSee the site
- Registry title
- Phase I study of 225Ac-PSMA I&T in prostate cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 30 people, planned
- Started
- 1 Feb 2022
- Planned end
- 1 Jan 2026
- Type of study
- Interventional
- Record updated
- 30 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult men with metastatic prostate cancer to test 225Ac-PSMA I&T in a phase I study.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Metastatic prostate cancer
Where in Netherlands
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests a radioactive medicine, 225Ac-PSMA I&T, in men with spreading prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 30 June 2025